Abbott Laboratories (ABT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Annual meeting scheduled to be held virtually on April 24, 2026, with instructions for online participation and voting provided.
Proxy materials and the 2025 Annual Report are available online, with options for electronic or paper delivery.
Shareholders are encouraged to review all proxy materials before voting and can help the environment by opting for electronic delivery.
Voting matters and shareholder proposals
Election of 12 directors is up for vote, with the board recommending a vote FOR all nominees.
Ratification of Ernst & Young LLP as external auditors is proposed.
Advisory vote on executive compensation (Say on Pay) is included.
Approval of the 2026 Incentive Stock Program and the 2026 Employee Stock Purchase Plan for Non-U.S. Employees are on the agenda.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and all other proposals.
List of 12 director nominees provided, including N. Ahuja, C. Babineaux-Fontenot, and others.
Latest events from Abbott Laboratories
- Q2 2026 sales up 13% to $12.6B, adjusted EPS beats, guidance raised on diagnostics strength.ABT
Q2 2026 - Q1 2026 sales up 7.8% to $11.16B, driven by Medical Devices and Exact Sciences acquisition.ABT
Q1 2026 - Proxy covers director elections, auditor ratification, equity plans, and strong ESG focus.ABT
Proxy Filing - 2026 guidance targets 10% EPS growth and 7% organic sales growth, led by innovation and expansion.ABT
Q4 2025 - Board recommends approval of all proxy items, citing strong returns and ESG progress.ABT
Proxy Filing - Q3 sales up 4.9% to $10.6B, Medical Devices led growth, and adjusted EPS guidance increased.ABT
Q3 2024 - Q2 sales up 4% to $10.4B, driven by double-digit Medical Devices growth and raised guidance.ABT
Q2 2024 - Q1 2025 saw strong sales and EPS growth, led by Medical Devices and Nutrition.ABT
Q1 2025 - Double-digit EPS growth and robust organic sales momentum expected to continue in 2025.ABT
Q4 2024